KEROS THERAPEUTICS INC (KROS)
Health Care · Clinical-stage biopharmaceutical / rare disease therapeutics · NASDAQ
Clinical-stage biotech developing TGF-beta-targeting protein therapeutics for rare neuromuscular and hematologic diseases with one Phase 3 program licensed to Takeda.
What KEROS THERAPEUTICS INC does
Keros Therapeutics is a clinical-stage biopharmaceutical company developing protein therapeutics that target dysfunctional signaling of the transforming growth factor-beta (TGF-β) family of proteins. The company's lead candidate, rinvatercept (KER-065), inhibits myostatin and activin A to treat neuromuscular diseases including Duchenne muscular dystrophy and amyotrophic lateral sclerosis. Its most advanced candidate, elritercept (KER-050), is an ActRIIA ligand trap licensed to Takeda Pharmaceuticals for treating cytopenias in myelodysplastic syndromes and myelofibrosis.
Themes: ["TGF-beta signaling / muscle regeneration","Duchenne muscular dystrophy (DMD)","Amyotrophic lateral sclerosis (ALS)","Myelodysplastic syndromes (MDS)","Myelofibrosis / hematologic malignancies","Rare genetic / neuromuscular diseases"]
Fundamentals
- Price$12.03 as of 2026-07-09 close
- Market cap$234M as of 2026-07-10
- 1-year return-16.1% as of 2026-07-09 close
- P/E2.68 as of 2026-07-10
- Net margin-256.6% as of 2026-07-10
- ROE-17.0% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)-84.5% as of 2026-07-10
- Beta1.00 as of 2026-07-10
Key risks (from latest filing)
["Clinical development risk: rinvatercept is in Phase 1 with Phase 2 in DMD not expected until Q3 2026; elritercept Phase 3 RENEW trial is ongoing with uncertain outcomes; failure to achieve clinical efficacy or safety profile would delay or halt development","Revenue dependence on Takeda partnership: elritercept commercialization is exclusively licensed to Takeda; company receives milestone payments and potential royalties but has limited control over development and commercial success","Cash burn and unprofitability: company has generated no product revenue to date, operates at significant net loss (-256.6% net margin), and faces capital requirements to fund ongoing clinical trials and operations"]
Competitors & peers
- Acceleron Pharma (PULM) – now Merck subsidiary; pioneered TGF-β/ActRIIA approach with Reblozyl
- Sarepta Therapeutics (SRPT) – gene therapies and therapeutics for DMD
- Invitae / Translate Bio – rare genetic disease focus
- Agios Pharmaceuticals (AGIO) – rare disease drug development
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.